Accelerate Diagnostics (NASDAQ:AXDX – Get Free Report) and Prenetics Global (NASDAQ:PRE – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, earnings, analyst recommendations and dividends.
Insider and Institutional Ownership
17.1% of Accelerate Diagnostics shares are held by institutional investors. Comparatively, 25.0% of Prenetics Global shares are held by institutional investors. 43.6% of Accelerate Diagnostics shares are held by insiders. Comparatively, 7.8% of Prenetics Global shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Analyst Recommendations
This is a summary of recent ratings and price targets for Accelerate Diagnostics and Prenetics Global, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Accelerate Diagnostics | 0 | 1 | 1 | 0 | 2.50 |
| Prenetics Global | 0 | 0 | 1 | 0 | 3.00 |
Profitability
This table compares Accelerate Diagnostics and Prenetics Global’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Accelerate Diagnostics | -452.28% | N/A | -205.15% |
| Prenetics Global | -193.60% | -11.15% | -9.03% |
Volatility and Risk
Accelerate Diagnostics has a beta of 0.53, suggesting that its stock price is 47% less volatile than the S&P 500. Comparatively, Prenetics Global has a beta of -0.28, suggesting that its stock price is 128% less volatile than the S&P 500.
Valuation and Earnings
This table compares Accelerate Diagnostics and Prenetics Global’s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Accelerate Diagnostics | $12.06 million | 2.52 | -$61.62 million | ($4.07) | -0.34 |
| Prenetics Global | $21.74 million | 2.42 | -$62.72 million | ($4.80) | -1.20 |
Accelerate Diagnostics has higher earnings, but lower revenue than Prenetics Global. Prenetics Global is trading at a lower price-to-earnings ratio than Accelerate Diagnostics, indicating that it is currently the more affordable of the two stocks.
Summary
Accelerate Diagnostics beats Prenetics Global on 7 of the 13 factors compared between the two stocks.
About Accelerate Diagnostics
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona.
About Prenetics Global
Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies. In addition, the company, through its equity interests in ACT Genomics Holdings Company Limited, is involved in genomic profiling of solid tumors through ACTOnco. Prenetics Global Limited was founded in 2007 and is based in Quarry Bay, Hong Kong.
Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
